Insect Cells Could Increase Flu-Vaccine Development
Influenza vaccines can be produced faster using a new insect cell-based technology compared with traditional egg-based processes, according to scientists in Vienna, Austria.
Influenza vaccines can be produced faster using a new insect cell-based technology than traditional egg-based processes, according to scientists in Vienna, Austria. The new technique involves using insect cells to create recombinant influenza virus-like particles (VLPs) that resemble virus particles, but lack the viral nucleic acid, which means they are not infectious.
"Recent outbreaks of influenza highlight the importance of a rapid and sufficient vaccine supply for pandemic and inter-pandemic strains," said Florian Krammer, co-author of the University of Natural Resources and Applied Life Science study in Vienna, in a press statement.
Traditional influenza vaccines are produced in embryonated chicken eggs and although they can be manufactured in sufficient quantities for seasonal influenza strains, the method may be insufficient in a pandemic situation because of limited egg supply.
Using the new insect cell-based method, the Austrian team took only 10 weeks to produce swine-origin pandemic H1N1 swine-flu influenza VLPs for immunological studies in mice. Conventional production methods, however, would take months. Using insect cells also overcomes some of the problems associated with egg-based methods, such as allergic reactions to egg proteins and biosafety issues.
"Our work demonstrates that recombinant influenza VLPs are a very fast, safe and efficient alternative to conventional influenza vaccines and represents a significant new approach for newly emerging influenza strains such as H1N1 or H5N1," said Krammer in the release.
The study appears in the Biotechnology Journal.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Your Ultimate Guide for CMC Testing Support for Gene and Cell Therapy
November 21st 2024Explore the complexities of gene and cell therapy development with our comprehensive guide to Chemistry, Manufacturing, and Controls (CMC) testing. Learn how our expertise ensures the safety, potency, and quality of advanced therapies, supporting your journey from product development through regulatory approval.
